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Abstract 34 
 35 
The Himalayan Sherpas, a human population of Tibetan descent, are highly adapted to life in the 36 
hypobaric hypoxia of high altitude. Mechanisms involving enhanced tissue oxygen delivery in 37 
comparison with Lowlander populations, have been postulated to play a role in such adaptation. 38 
Whether differences in tissue oxygen utilization (i.e. metabolic adaptation) underpin this 39 
adaptation is not however known. We sought to address this issue, applying parallel molecular, 40 
biochemical, physiological and genetic approaches to the study of Sherpas and native Lowlanders, 41 
studied before and during exposure to hypobaric hypoxia on a gradual ascent to Mount Everest 42 
Base Camp (5,300 m). When compared with Lowlanders, Sherpas demonstrated a lower capacity 43 
for fatty acid oxidation in skeletal muscle biopsies, along with enhanced efficiency of oxygen 44 
utilization, improved muscle energetics and protection against oxidative stress. This in part 45 
appeared to be related to a putatively advantageous allele for the PPARA gene, which was 46 
enriched in the Sherpas compared with the Lowlanders. Our findings suggest that metabolic 47 
adaptations underpin human evolution to life at high altitude, and could impact upon our 48 
understanding of human diseases in which hypoxia is a feature.   49 
 50 
 51 
 52 
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 54 
 55 
186 words (250 max) 56 
  57 
HORSCROFT et al                      Sherpa Metabolism and Altitude Adaptation                                   
3 
 
Significance Statement 58 
A relative fall in tissue oxygen levels (hypoxia) is a common feature of many human diseases 59 
including heart failure, lung diseases, anemia and many cancers, and can compromise normal 60 
cellular function. Hypoxia also occurs in healthy humans at high altitude due to low barometric 61 
pressures. Human populations resident at high altitude in the Himalayas have evolved 62 
mechanisms that allow them to survive and perform, including adaptations that preserve oxygen 63 
delivery to the tissues. Here we studied one such population, the Sherpas, and found metabolic 64 
adaptations, underpinned by genetic differences, which allow their tissues to use oxygen more 65 
efficiently, thereby conserving muscle energy levels at high altitude, and possibly contributing to 66 
the superior performance of elite climbing Sherpas at extreme altitudes.  67 
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\body 68 
Introduction 69 
At high altitude, low barometric pressure is accompanied by a fall in the partial pressure of 70 
inspired O2, resulting in hypobaric hypoxia. The cellular response to hypoxia is orchestrated by the 71 
Hypoxia Inducible Factor (HIF) transcription factors, with HIF-1α and HIF-2α respectively mediating 72 
responses to short-term and more sustained hypoxia (1). In normoxia, prolyl-hydroxylases target 73 
HIFα subunits for destruction (2). Under low O2 partial pressures, however, HIF-1α/HIF-2α are 74 
stabilized and dimerize with the nuclear HIF-1β subunit. This dimer interacts with hypoxia-75 
response elements in promoter regions to increase expression of specific genes, e.g. EPO 76 
(encoding erythropoietin) and VEGFA (vascular endothelial growth factor A) (3). 77 
 78 
The Tibetan Plateau has an average altitude of some 4,500 m. Humans were first present on the 79 
Plateau ~30,000 years ago, with the earliest permanent settlements appearing 6-9,000 years ago 80 
(4) – a period sufficient to drive the natural selection of genetic variants (and associated features) 81 
favouring survival and performance in sustained hypoxia (5, 6). Evidence supports the selection of 82 
genetic variants encoding components of the hypoxia-inducible factor (HIF) pathway, such as 83 
EPAS1 (encoding HIF-2α) (7) and EGLN1 (prolyl-hydroxylase-2, PHD2) (8) in Tibetan populations. 84 
One population, the Sherpas, migrated from Tibet to eastern Nepal ~500 years ago and exhibit 85 
remarkable physical performance at extreme altitude (9).  86 
 87 
Whilst the human adaptive response to hypoxia is incompletely understood, mitigation against the 88 
fall in convective O2 delivery plays an important role. In Lowlanders, increased ventilation and 89 
cardiac output, and the production of more O2-carrying red blood cells help to sustain O2 delivery 90 
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and content (10, 11). Likewise, exhaled concentrations of nitric oxide (NO), a key regulator of 91 
blood flow, are higher in Tibetans than Lowlanders (12), as are circulating NO metabolites and limb 92 
blood flow (13). The rise in red cell mass in response to hypobaric hypoxia is not as great in 93 
Tibetans as in Lowlanders, however (14, 15), suggesting that adaptation involves more than just 94 
increased O2 delivery. In fact, acclimatization also involves alterations in O2 use. In Lowlander 95 
muscle, mitochondrial density declines with sustained exposure to extreme altitude (16-18), whilst 96 
exposure to more moderate high altitude is associated with a reprogramming of muscle 97 
metabolism (19) even without altered mitochondrial density (20), including downregulation of 98 
electron transfer complexes (19) and tricarboxylic acid (TCA) cycle enzymes (21), loss of fatty acid 99 
oxidation (FAO) capacity (19, 20) and improved oxidative phosphorylation coupling efficiency (20). 100 
Sherpas have lower muscle mitochondrial densities than unacclimatized Lowlanders (22), but little 101 
is known of their metabolic adaptation to hypoxia, or any genetic selection which might underpin 102 
it. A role has been suggested for peroxisome proliferator-activated receptor alpha (PPARα), a 103 
transcriptional regulator of FAO in liver, heart and muscle. HIF downregulates PPARα in some 104 
tissues (23), whilst there is evidence for selection of variants in its encoding gene (PPARA) in some 105 
Tibetan subgroups (8, 24). We hypothesized that metabolic adaptation, and PPARα in particular, 106 
play a central role in the Sherpa adaptation to hypobaric hypoxia.   107 
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Results and Discussion 108 
 109 
Selection of PPARA Variants in Sherpas 110 
 111 
Lowlander and Sherpa subjects were participants of the research expedition, Xtreme Everest 2 112 
(25). The Lowlanders comprised 10 investigators selected to operate the Everest Base Camp (EBC) 113 
laboratory. Sherpas (n = 15) were a sex-matched (73% male, cf. 70% in Lowlanders) and age-114 
matched (26.8 ± 1.2 yr, cf. 28.0 ± 1.6 yr in Lowlanders) group living in Kathmandu and the 115 
Solukhumbu and Rolwaling valleys. No subject ascended higher than 4,200 m in the 3 months 116 
preceding the trek, nor above 2,500 m in the preceding 3 weeks. In addition, Sherpas presented 117 
evidence of sole Sherpa ancestry for 2 generations (i.e. 4 Sherpa grandparents). The frequency of 118 
putatively advantageous PPARA alleles (8) was higher in Sherpas than Lowlanders (Fig. 1A; Table 119 
S1), with genotype frequencies of the cohorts being significantly different at 2 single nucleotide 120 
polymorphisms (SNPs), rs6520015 and rs7292407 (P = 0.0091), though not rs9627403. This 121 
reflected patterns reported in some other Tibetan groups (26). 122 
 123 
Muscle Hypoxia and Circulating NO Metabolites 124 
Baseline testing, including blood sampling, muscle biopsy sampling, high-resolution respirometry 125 
of permeabilized muscle fibers and oral glucose tolerance tests (OGTT) took place in London (35 126 
m) for Lowlanders and Kathmandu (1,300 m) for Sherpas (25). All subjects then followed an 127 
identical ascent (Fig. 1B) from Kathmandu to EBC (5,300 m) whereupon further testing took place 128 
at an early timepoint (A1; 15-20 d post-departure for Lowlanders, 11-12 d for Sherpas), and a late 129 
timepoint (A2; 54-59 d post-departure) for Lowlanders only. At the time of sampling, both groups 130 
had passed through the acute phase of hypoxic exposure (<24 h) (1) and had been sufficiently 131 
exposed to chronic hypoxia for acclimatization to have occurred. Indeed, arterial hemoglobin-O2 132 
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saturations were similarly low in both groups (Fig. 1C), whilst muscle expression of the HIF-target 133 
VEGFA increased in all subjects (Fig. 1D), indicating a molecular response to hypoxia. Following 134 
measurements at A1, the Lowlanders remained at EBC for 2 months to carry out research, 135 
presenting an opportunity to collect data pertaining to longer-term metabolic acclimatization. 136 
Interestingly, VEGFA expression was no longer elevated by this timepoint, suggesting further 137 
acclimatization had occurred.  138 
To our surprise, there were no differences in circulating N-nitrosamine (RNNO), S-nitrosothiol 139 
(RSNO), nitrate (NO3-) or nitrite (NO2-) concentrations between Lowlanders and Sherpas at baseline 140 
(Fig. 1E-H). In Lowlanders, a transient increase in plasma RNNO levels occurred upon arrival at EBC 141 
(P < 0.05) but disappeared by the later timepoint (Fig. 1E). In Sherpas, plasma nitrate levels fell at 142 
altitude (P < 0.05; Fig. 1G) and nitrite levels increased (P < 0.05; Fig. 1H), whilst in Lowlanders 143 
nitrite levels fell by the later timepoint (P < 0.05). The absence of large differences in NO 144 
metabolites between the groups at baseline or at altitude, suggested an adaptive phenotype in 145 
Sherpas that is distinct from other Tibetan highlanders (13). 146 
 147 
Lower Fatty Acid Oxidation Capacity in Sherpas 148 
Skeletal muscle biopsies revealed marked differences in gene expression and FAO capacity 149 
between Sherpas and Lowlanders. Expression of PPARA mRNA was 48% lower in Sherpas than 150 
Lowlanders (P < 0.05; Fig. 2A), thus the putatively advantageous PPARA allele is associated with 151 
diminished expression. Correspondingly, expression of the PPARα target CPT1B was 32% lower in 152 
Sherpas at baseline compared with Lowlanders (P < 0.05; Fig. 2B). The PPARA gene contains 139 153 
SNPs. rs6520015 is one of the tagging SNPs reported by Simonson et al (8), however it appears to 154 
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be a non-coding variant. It is thus uncertain whether the SNP itself affects transcriptional 155 
regulation, or whether it tags a functional variant elsewhere, modifying expression or mRNA 156 
stability. Ascent to EBC did not alter PPARA expression in either group, yet despite this CPT1B 157 
expression decreased by 44% in Lowlanders (P < 0.05) but did not decrease further in Sherpas. This 158 
suggests that the Lowlander response to hypoxia involves decreased PPARα transcriptional activity 159 
without changes in PPARA expression, similar to hypoxic rat skeletal muscle (27).  160 
Gene expression changes do not necessarily reflect protein levels or activity, therefore we 161 
measured activity of the β-oxidation enzyme 3-hydroxyacyl-CoA dehydrogenase (HADH), finding it 162 
to be 27% lower in Sherpas than Lowlanders at baseline (P < 0.05), and not changing in either 163 
group following ascent (Fig. 2C). Moreover, fatty acid oxidative phosphorylation capacity (FAOP) 164 
was measured as the oxygen flux in saponin-permeabilized muscle fibers with octanoylcarnitine, 165 
malate and ADP, using high-resolution respirometry (28). FAOP was 24% lower in Sherpas than 166 
Lowlanders at baseline (P < 0.01), and did not change in either group following ascent (Fig. 2D, Fig. 167 
S1). Ex vivo measurements may be particular to assay conditions used, therefore we also 168 
measured muscle metabolite levels to indicate changes in metabolism in vivo. Total carnitine 169 
concentrations decreased in Lowlanders with time spent at EBC (P < 0.05), though were not 170 
significantly different to those in Sherpas at baseline (Fig. 2E). The ratio of long chain acylcarnitines 171 
to total carnitines, however, increased in Lowlanders with time at altitude (P < 0.05; Fig. 2F), 172 
suggesting incomplete FAO results in accumulation of potentially-harmful lipid intermediates (29). 173 
In Sherpa muscle, however, the long chain acylcarnitine to total carnitine ratio was lower than in 174 
Lowlanders at baseline (P < 0.05), perhaps resulting from lower expression of CPT-1. In further 175 
contrast with Lowlanders, the long chain acylcarnitine to total carnitine ratio remained low in 176 
Sherpa muscle at altitude. 177 
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 178 
TCA Cycle Regulation at High Altitude 179 
We therefore sought to understand whether there were differences between the populations in 180 
other aspects of mitochondrial metabolism. The TCA cycle enzyme citrate synthase (CS) is a 181 
candidate marker of mitochondrial content in human muscle (30). At baseline, Sherpas had a 26% 182 
lower muscle CS activity than Lowlanders (P < 0.05; Fig. 3A), in agreement with findings of 17-33% 183 
lower mitochondrial volume density in Sherpa vastus lateralis compared with Lowlanders (22). In 184 
accordance with lower CS activity, concentrations of 6- and 5-carbon intermediates downstream 185 
of CS (citrate, aconitate, isocitrate, α-ketoglutarate) were lower in Sherpas than Lowlanders (P < 186 
0.001). However, concentrations of 4-carbon intermediates (succinate, fumarate, malate, 187 
oxaloacetate) were not different (Fig 3B-I). This suggests an alternative strategy to supply the TCA 188 
cycle with succinate. Intriguingly, recent analysis of a large SNP dataset from low and high altitude-189 
adapted populations in the Americas and Asia (31) aimed to identify pathways of convergent 190 
evolution, and highlighted fatty acid ω-oxidation as the most significant cluster of overlapping 191 
gene sets between high altitude groups (32). ω-oxidation, is normally a minor pathway in 192 
vertebrates, becoming more important when β-oxidation is defective (33), and through successive 193 
cycles oxidizes fatty acids to adipate and succinate in the endoplasmic reticulum, after which 194 
succinate enters the mitochondria with anaplerotic regulation of the TCA cycle (34). 195 
 196 
Upon ascent to altitude, 6- and 5-carbon TCA cycle intermediates increased in Sherpa muscle (P < 197 
0.05; Fig. 3B-E), suggesting improved coupling of intermediary metabolism, TCA cycle and 198 
oxidative phosphorylation. In Lowlanders, however, citrate, aconitate and isocitrate decreased at 199 
altitude (P < 0.05; Fig. 3B-D), despite no significant change in CS activity, perhaps reflecting 200 
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impairments upstream. Interestingly, α-ketoglutarate concentrations were maintained in 201 
Lowlanders at altitude (Fig. 3E), despite decreased succinate downstream, which could be 202 
explained by the fall in both α-ketoglutarate dehydrogenase and isocitrate dehydrogenase, 203 
reported previously in Lowlanders following an identical ascent to EBC (21). α-ketoglutarate plays 204 
regulatory roles in hypoxia, including a suppression of HIF stabilization (35), but also supporting 205 
glutathione synthesis (36). Taken together, these results indicate different TCA cycle regulation in 206 
Sherpas and Lowlanders. The replete TCA cycle of Sherpas at altitude contrasts sharply with the 207 
depletion of TCA cycle intermediates in Lowlanders, and suggests a coupling of the TCA cycle in 208 
Sherpa muscle to their distinct intermediary substrate metabolism. 209 
 210 
Greater Mitochondrial Coupling Efficiency in Sherpas 211 
To further understand whether mitochondrial function differs between Sherpas and Lowlanders, 212 
we used high-resolution respirometry, to probe electron transfer system (ETS) capacity and 213 
coupling efficiency in permeabilized muscle fibers. At baseline, there was no significant difference 214 
between the two groups in OXPHOS or ETS capacities with either malate and glutamate (N-215 
pathway through Complex I) or succinate as substrates (S-pathway through Complex II; Fig. 4A,B; 216 
Fig. S2), but Sherpas had a lower OXPHOS capacity with malate, glutamate and succinate 217 
combined to reconstitute TCA cycle function (NS-pathway; P < 0.01; Fig. 4C). There were no early 218 
changes in either group upon ascent. By the later timepoint however, succinate-linked respiration 219 
had fallen in Lowlanders (P < 0.05), consistent with previous findings of decreased succinate 220 
dehydrogenase (Complex II) levels in subjects with sustained exposure >5,300 m (21). 221 
 222 
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In addition, we measured muscle fiber respiration in the absence of ADP (LEAK), i.e. O2 223 
consumption without ADP phosphorylation. Expressing LEAK relative to OXPHOS capacity, it is 224 
possible to calculate OXPHOS coupling efficiency (37, 38). At baseline, Sherpa muscle mitochondria 225 
had lower LEAK respiration and greater coupling efficiency than Lowlander mitochondria (P < 226 
0.001; Fig. 4D,E), indicating more efficient use of O2. Upon ascent to EBC and with sustained time 227 
at altitude, LEAK decreased in Lowlanders (P < 0.01), though it remained higher than in Sherpas 228 
(Fig. 4D), and coupling efficiency improved (P < 0.05; Fig. 4E). In Sherpas at altitude, LEAK did not 229 
change although coupling efficiency decreased (P < 0.01). One possible explanation for these 230 
differences in coupling efficiency might be the altered expression of uncoupling protein 3 (UCP3). 231 
UCP3 is a transcriptional target of PPARα and lower UCP3 levels at altitude might improve the 232 
efficiency of O2 utilization. In previous studies, however, muscle UCP3 expression increased with 233 
acute hypoxia (17, 39), which may offer some protective benefit considering its possible role as an 234 
antioxidant (39). Notably though, UCP3 levels decreased with more sustained exposure to extreme 235 
altitude (17). Here, UCP3 was upregulated in Sherpas at altitude in association with decreased 236 
coupling efficiency (P < 0.05; Fig. 4F). However, UCP3 expression also increased in Lowlanders in 237 
the short-term (P < 0.01) in whom there was decreased LEAK respiration. Moreover, UCP3 238 
expression returned to baseline in Lowlanders with longer-term exposure with no further change 239 
in LEAK respiration. Overall, our results indicate that Sherpa muscle mitochondria are 240 
characterized by a lower OXPHOS capacity and greater, albeit declining, efficiency, whilst in 241 
Lowlanders OXPHOS efficiency improved with acclimatization. 242 
 243 
Glycolysis and Glucose Metabolism 244 
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Next we investigated the capacity to derive cellular energy via glycolysis, which is increased in 245 
hypoxic cells (40), as this may allow ATP levels to be maintained when O2 is limited. Hexokinase 246 
activity was the same in both groups at baseline, and did not change at altitude (Fig. 5A), however 247 
lactate dehydrogenase (LDH) activity was 48% higher in Sherpa muscle than in Lowlanders (P < 248 
0.05), indicating greater capacity for anaerobic lactate production (Fig. 5B). Fasting blood glucose 249 
was the same in Sherpas and Lowlanders at baseline, and decreased upon ascent in Lowlanders (P 250 
< 0.01; Fig. 5C), who also showed faster clearance of glucose during an OGTT (P < 0.001; Fig. 5D) in 251 
agreement with previous reports (41). In Sherpas, however, there was no indication of altered 252 
glucose homeostasis. Meanwhile, over time at altitude glycolytic intermediates increased in 253 
Lowlander muscle (Fig. 5E) with increased glucose-6-phosphate/fructose-6-phosphate and 2-254 
phosphoglycerate/3-phosphoglycerate (Table S2). In contrast, total glycolytic intermediates did 255 
not change in Sherpa muscle, although 2-phosphoglycerate/3-phosphoglycerate decreased. These 256 
findings, might to some extent be explained by altered HIF activities. Many genes encoding 257 
glycolytic enzymes are upregulated by HIF-1 (42), whilst hypoglycemia is seen in Chuvash 258 
polycythemia, an autosomal recessive disorder in which HIF degradation is impaired (43). Taken 259 
together, our findings suggest an increased reliance on glucose by Lowlanders under resting 260 
conditions at altitude compared with Sherpas, but a greater capacity for lactate production in 261 
Sherpas which may prove effective upon exertion. 262 
 263 
Energetics and Oxidative Stress 264 
Finally, to understand the implications of Sherpa metabolic adaptation we investigated muscle 265 
energetics and redox homeostasis. Lowlanders at altitude showed progressive loss of muscle 266 
phosphocreatine (PCr; P < 0.001; Fig. 6A), indicating a loss of energetic reserve, which may relate 267 
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to downregulation of muscle creatine kinase, as reported previously (21). By contrast, in Sherpa 268 
muscle, PCr increased at altitude (P < 0.01). Similarly, Sherpa muscle ATP levels, which were lower 269 
than in Lowlanders at baseline (P < 0.05), increased at altitude (P < 0.001; Fig. 6B), illustrating that 270 
Sherpa metabolism is better suited to maintaining muscle energetics at altitude than Lowlander 271 
metabolism in either the short-term or following acclimatization. Moreover, with short-term 272 
exposure, markers of oxidative stress (reduced/oxidized glutathione and methionine sulfoxide) 273 
increased in Lowlander muscle, but not Sherpa muscle (Fig. 6C,D), indicating superior redox 274 
homeostasis in the Sherpas. Antioxidant protection may represent another outcome of convergent 275 
evolution, having been reported in Andean subjects in association with protection of fetal growth 276 
(44), whilst glutathione levels are raised in Chuvash polycythemia suggesting a possible role for HIF 277 
activation (45). 278 
 279 
Conclusions 280 
 281 
It has long been suspected that Sherpa people are better adapted to life at high altitude than 282 
Lowlanders (46). Recent findings have suggested a genetic basis to adaptation in populations 283 
around the world (6), and here we show that Sherpas have a metabolic adaptation associated with 284 
improved muscle energetics and protection against oxidative stress. Genetic selection on the 285 
PPARA gene is associated with decreased expression, and thus lower fatty acid β-oxidation and 286 
improved mitochondrial coupling compared with Lowlanders, with a possible compensatory 287 
increase in fatty acid ω-oxidation. Sherpas also have a greater capacity for lactate production. 288 
With acclimatization to altitude, Lowlanders accumulate potentially-harmful lipid intermediates in 289 
muscle as a result of incomplete β-oxidation, alongside depletion of TCA cycle intermediates, 290 
accumulation of glycolytic intermediates, a loss of PCr despite improved mitochondrial coupling, 291 
HORSCROFT et al                      Sherpa Metabolism and Altitude Adaptation                                   
14 
 
and a transient increase in oxidative stress markers. In Sherpas, however, there are remarkably 292 
few changes in intermediary metabolism at altitude, but increased TCA cycle intermediates and 293 
PCr and ATP levels, with no sign of oxidative stress.   294 
 295 
Genetic selection, by definition, requires an increased likelihood of advantageous gene variants 296 
being passed on to offspring. This might occur if the disadvantageous variant is associated with 297 
poorer survival to reproductive age and beyond, including greater fetal/neonatal mortality. 298 
Evidence supports precisely such effects with fetal growth at altitude being poorer in Lowlander 299 
populations than many native highlanders (47), including Tibetans (48) and Sherpas (49). Likewise, 300 
gene variants may affect survival through childhood or fecundity/fertility in the hypoxic 301 
environment. We cannot speculate on the mechanism by which PPARA variants prove 302 
advantageous, however PPAR isoforms are expressed in the placenta (50) and influence female 303 
reproductive function (51). It would be of interest to seek association of the PPARA variants with 304 
birth weight and measures of placentation in high altitude natives and Lowlanders exposed to 305 
hypoxia.  306 
 307 
Our findings suggest a metabolic basis to Sherpa adaptation, which may permit the population to 308 
survive and perform at high altitude. Such adaptations may also underpin the superior 309 
performance of elite climbing Sherpas at extreme high altitude. 310 
311 
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Materials and Methods 312 
 313 
Subjects were selected from the participants of Xtreme Everest 2 (25). All Lowlanders were born 314 
and lived below 1,000 m, not descended from a high altitude-dwelling population and of European 315 
(Caucasian) origin. Subjects gave written consent, and underwent medical screening. All protocols 316 
were approved by UCL Research Ethics Committee and Nepal Health Research Council. Vastus 317 
lateralis biopsies were taken from the mid-thigh, muscle fibers prepared for respirometry (28) and 318 
respiration measured using substrate-uncoupler-inhibitor titrations (Tables S3, S4). Enzyme 319 
activities were assayed as described (27). RNA was extracted and Taqman® assays used to analyse 320 
gene expression (Table S5). For metabolite analysis, a methanol/chloroform extraction (52) was 321 
followed by liquid chromatography mass spectrometry (LC-MS). OGTTs were carried out on fasted 322 
subjects on the day after biopsies. Blood plasma NO metabolites were quantified as described 323 
(53). Genomic DNA was isolated from whole blood and PPARA SNPs genotyped using TaqMan® for 324 
allelic discrimination (Applied Biosystems, UK; Table S1). To compare cohorts at baseline, an 325 
unpaired two-tailed Student’s t-test was used (significance at P ≤ 0.05). Genotype frequencies 326 
were compared using a Chi-squared test. To assess the effects of altitude, a one-way ANOVA with 327 
repeated measures was used. Post-hoc pairwise comparisons were carried out with a Tukey 328 
correction.  329 
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Figure Legends 463 
Figure 1  Subject genetics, ascent profile, arterial blood O2 saturation, muscle hypoxia and 464 
circulating NO metabolites. A) Genotypes of Lowlanders and Sherpas at 3 PPARA 465 
SNPs - subjects homozygous for the putatively advantageous allele in black, 466 
heterozygous subjects in gray and subjects homozygous for the non-advantageous 467 
allele in white (digits in segments refer to number of subjects with genotype); B) 468 
Ascent profile including timing of biopsies; C) Arterial hemoglobin-O2 saturations; 469 
D) Muscle VEGFA expression, and E-H) plasma nitrogen oxides in Lowlanders (L) 470 
and Sherpas (S) at baseline (B) and early (A1) and late (A2) altitude. Mean ± SEM 471 
(n = 4-15).   †P ≤ 0.05; †††P ≤ 0.001 B vs A1 within cohort. ΔP ≤ 0.05 A1 vs A2 within 472 
cohort. 473 
Figure 2  Fatty acid oxidation and regulation in muscle. A) PPARA expression; B) CPT1B 474 
expression; C) HADH activity; D) Oxidative phosphorylation with 475 
octanoylcarnitine&malate (FAOP); E) Total carnitine; F) Long chain/total carnitine 476 
ratio in Lowlanders and Sherpas. Gene expression and carnitine levels are 477 
expressed relative to Lowlanders at baseline. Mean ± SEM (n = 6-13). *P ≤ 0.05; 478 
**P ≤ 0.01 Lowlanders vs Sherpas at baseline. †P ≤ 0.05 baseline vs altitude within 479 
cohort. 480 
 481 
Figure 3  TCA intermediates and activity in muscle. A) Citrate synthase activity and B-I) TCA 482 
cycle intermediates in Lowlanders and Sherpas. Metabolite levels are expressed 483 
relative to Lowlanders at baseline. Mean ± SEM (n = 7-14). *P ≤ 0.05; **P ≤ 0.01; 484 
***P ≤ 0.001 Lowlanders vs Sherpas at baseline. †P ≤ 0.05; ††P ≤ 0.01; baseline vs 485 
altitude within cohort. 486 
 487 
Figure 4 Mitochondrial oxygen consumption, efficiency and uncoupling protein expression. 488 
A) N-OXPHOS (GMP), B) S-ETS capacity (SE) and C) NS-OXPHOS capacity (GMSP) in 489 
permeabilized muscle fibers from Lowlanders and Sherpas. D) 490 
Octanoylcarnitine&malate-supported LEAK (FAOL) and E) OXPHOS coupling 491 
efficiency. F) Muscle UCP3 expression relative to Lowlanders at baseline. Mean ± 492 
SEM (n = 7-11). **P ≤ 0.01; ***P ≤ 0.001 Lowlander vs Sherpas at baseline. †P ≤ 493 
0.05; ††P ≤ 0.01 baseline vs altitude within cohort. ΔP ≤ 0.05; ΔΔP ≤ 0.01 altitude 1 494 
vs 2 within cohort. 495 
 496 
Figure 5 Muscle glycolysis and blood glucose homeostasis. A) Hexokinase and B) Lactate 497 
dehydrogenase activity. C) Fasting blood glucose and D) glucose clearance during 498 
OGTT. E) Total muscle glycolytic intermediates relative to Lowlanders at baseline. 499 
Mean ± SEM (n = 5-14). *P ≤ 0.05 Lowlanders vs Sherpas at baseline. †P ≤ 0.05; ††P 500 
≤ 0.01; †††P ≤ 0.001 baseline vs altitude within cohort. 501 
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Figure 6 Muscle energetics and oxidative stress. A) Phosphocreatine, B) ATP, C) 502 
Oxidized/reduced glutathione (GSSG/GSH) and D) Sulfoxide/total methionine 503 
(MetSO/Met), all expressed relative to Lowlanders at baseline. Mean ± SEM (n = 8-504 
14).  ††P ≤ 0.01; †††P ≤ 0.001 baseline vs altitude within cohort. ΔP ≤ 0.05 altitude 505 
1 vs 2 within cohort. 506 
